Bicara Therapeutics (NASDAQ:BCAX) Announces Quarterly Earnings Results

Bicara Therapeutics (NASDAQ:BCAX) issued its earnings results on Thursday. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08), Zacks reports.

Bicara Therapeutics Price Performance

BCAX stock opened at $13.40 on Friday. Bicara Therapeutics has a 52 week low of $11.10 and a 52 week high of $28.09. The stock has a 50 day moving average of $13.04.

Analysts Set New Price Targets

Several analysts recently weighed in on BCAX shares. Wedbush restated an “outperform” rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a report on Thursday. HC Wainwright upped their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a report on Thursday, March 13th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Bicara Therapeutics has a consensus rating of “Buy” and an average price target of $36.50.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.